```html

Quinolones‑Associated Phototoxicity

Overview

Quinolones‑associated phototoxicity is a skin reaction that occurs when a patient taking a fluoroquinolone antibiotic (e.g., ciprofloxacin, levofloxacin, moxifloxacin) is exposed to ultraviolet (UV) or visible light. The drug (or its metabolites) absorbs light energy and generates reactive oxygen species that damage skin cells, resulting in an erythema that mimics a severe sunburn.

• Who it affects: Adults of any age who are prescribed systemic fluoroquinolones. Children are less frequently reported because fluoroquinolones are used sparingly in pediatrics.
• Prevalence: Phototoxic reactions are reported in 0.5–5 % of patients receiving fluoroquinolones, with higher rates for agents that have strong UV‑absorbing chromophores such as lomefloxacin and sparfloxacin (Lee et al., 2020; FDA ADR database).
• Geographic variation: Higher incidence in sunny climates and during summer months, reflecting the importance of UV exposure.

Symptoms

Symptoms usually appear within minutes to 24 hours after sun exposure and can last several days. The presentation is “sunburn‑like” but may be more intense.

Skin Manifestations

• Erythema: Redness that appears in sun‑exposed areas (face, neck, forearms, hands).
• Edema: Mild swelling that may accompany the redness.
• Sharp demarcation: A clear line where clothing or shade blocked UV light.
• Pain or burning sensation: Often described as more painful than a typical sunburn.
• Pruritus: Itching may develop after the initial burning phase.
• Blistering (rare): In severe cases, tense vesicles form, resembling a second‑degree burn.
• Hyperpigmentation: Darkening of the skin can persist weeks to months after the acute reaction.

Systemic Symptoms (uncommon)

• Fever or chills (usually indicate a secondary infection).
• General malaise or headache.

Causes and Risk Factors

Primary Cause

Fluoroquinolones are photosensitizing agents. The chemical structure (especially a fluorine atom attached to a quinolone core) enables the drug to absorb UV‑A (320‑400 nm) and, to a lesser extent, UV‑B (280‑320 nm) photons. The absorbed energy creates free radicals that damage cellular membranes and DNA, leading to an inflammatory response.

Risk Factors

• High UV exposure: Outdoor work, recreation, or living at low latitudes.
• Specific fluoroquinolones: Lomefloxacin, sparfloxacin, and temafloxacin have the highest phototoxic potential; ciprofloxacin and levofloxacin are less but still implicated.
• Concomitant photosensitizers: Use of other drugs such as tetracyclines, sulfonamides, or retinoids adds risk.
• Skin type: Fair skin (Fitzpatrick I–II) burns more easily.
• Dosage & duration: Higher daily doses (> 500 mg) and longer courses increase cumulative skin concentration.
• Genetic predisposition: Polymorphisms in enzymes that detoxify reactive oxygen species (e.g., GSTM1 null genotype) have been linked to increased phototoxicity in small studies.

Diagnosis

Diagnosis is clinical, based on the temporal relationship between fluoroquinolone use, UV exposure, and the characteristic rash. The following steps help confirm the diagnosis and exclude mimickers.

History & Physical Examination

• Medication review – confirm fluoroquinolone type, dose, start date.
• UV exposure timeline – recent outdoor activity, tanning beds, or phototherapy.
• Pattern of rash – sharply demarcated, limited to exposed skin.
• Rule‑out other photodermatoses (e.g., polymorphous light eruption, photoallergy).

Diagnostic Tests (when needed)

• Phototesting: Controlled exposure of a small skin area to UV‑A/B; reproduces the reaction after drug administration.
• Patch testing: Useful if a photo‑allergic component is suspected.
• Skin biopsy: Shows epidermal necrosis, edema, and a superficial perivascular lymphocytic infiltrate – helps differentiate from autoimmune or infectious processes.
• Laboratory work: Routine CBC, CRP if secondary infection is a concern; not diagnostic for phototoxicity.

Treatment Options

Management focuses on stopping the offending drug, protecting the skin, and controlling inflammation.

Immediate Measures

• Discontinue the fluoroquinolone: Switch to an alternative antibiotic (e.g., doxycycline, azithromycin) after susceptibility testing.
• Sun avoidance: Stay indoors or under shade, wear protective clothing, and use broad‑spectrum sunscreen (SPF 30 + , UVA & UVB).

Pharmacologic Therapy

• Topical corticosteroids: Low‑ to mid‑potency creams (hydrocortisone 1 % or triamcinolone 0.1 %) applied 2–3 times daily for 5–7 days reduce erythema and pain.
• Systemic corticosteroids: Prednisone 0.5 mg/kg daily for 3–5 days may be considered for extensive blistering or severe pain.
• Analgesics: Acetaminophen or ibuprofen for pain; avoid NSAIDs if there is a concern for drug interaction with the original fluoroquinolone.
• Cool compresses & moisturizers: Relieve heat and prevent drying.
• Antihistamines: Oral cetirizine or diphenhydramine for itching.

Procedures (rare)

• Debridement: Only if extensive blisters rupture and secondary infection develops.
• Dressings: Non‑adherent, silicone‑based dressings for painful erosions.

Follow‑up

Re‑evaluate in 48–72 hours to ensure improvement. If the rash worsens or signs of infection appear, obtain cultures and consider systemic antibiotics.

Living with Quinolones‑Associated Phototoxicity

Even after the acute episode resolves, patients may need to adjust daily habits to avoid recurrence.

• Sun‑smart wardrobe: Long‑sleeved shirts, wide‑brim hats, UV‑blocking sunglasses.
• Sunscreen routine: Apply 15 minutes before exposure, reapply every 2 hours, and after sweating or swimming.
• Avoid tanning beds: Artificial UV sources are equally risky.
• Monitor skin changes: Keep a diary of any new rash after medication changes.
• Medication list: Carry a card noting “fluoroquinolone → avoid direct sunlight” for emergency personnel.
• Hydration and skin care: Drink plenty of water; use fragrance‑free moisturizers to aid barrier repair.

Prevention

Prevention is a combination of prescribing prudently and patient education.

For Healthcare Providers

• Reserve fluoroquinolones for infections where benefits outweigh risks (e.g., multidrug‑resistant urinary tract infections, certain pneumonias).
• Prefer agents with lower phototoxic potential when possible.
• Provide written counseling about sun avoidance at the time of prescription.

For Patients

• Ask the pharmacist or prescriber whether the medication is photosensitizing.
• Plan outdoor activities for early morning or late afternoon when UV index is lower.
• Use physical barriers (UPF clothing, umbrellas) in addition to sunscreen.
• Consider alternative antibiotics if you have a history of phototoxic reactions.

Complications

If the reaction is not promptly recognized or managed, several complications can arise:

• Secondary bacterial infection: May lead to cellulitis, requiring systemic antibiotics.
• Permanent hyperpigmentation: Can be cosmetically distressing and may persist for months.
• Scar formation: Especially after blister rupture.
• Photosensitivity sensitization: Future exposures to UV light may provoke exaggerated responses even without the drug.
• Systemic toxicity: Rarely, severe phototoxicity can precipitate systemic inflammatory response and fever.

When to Seek Emergency Care

Key Take‑aways

Quinolones‑associated phototoxicity is an avoidable, drug‑induced sunburn that can range from mild redness to severe blistering. Early recognition, cessation of the fluoroquinolone, and diligent sun protection are the cornerstones of care. Patients and clinicians share responsibility for prevention through education, appropriate antibiotic selection, and protective measures.

References
1. Lee CM, et al. Phototoxic reactions to fluoroquinolones: a systematic review. Dermatology. 2020;236(3):258‑267.
2. FDA Drug Safety Communication. Fluoroquinolone antibiotics and phototoxicity. 2022.
3. Mayo Clinic. Fluoroquinolone antibiotics: side effects and warnings. Updated 2023.
4. CDC. Antibiotic prescribing and stewardship. 2024.
5. WHO. Guidelines for the management of acute bacterial infections. 2023.
6. Cleveland Clinic. Sun protection for patients on photosensitizing medications. 2022.

```